[go: up one dir, main page]

PE20010540A1 - COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES - Google Patents

COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES

Info

Publication number
PE20010540A1
PE20010540A1 PE2000000750A PE0007502000A PE20010540A1 PE 20010540 A1 PE20010540 A1 PE 20010540A1 PE 2000000750 A PE2000000750 A PE 2000000750A PE 0007502000 A PE0007502000 A PE 0007502000A PE 20010540 A1 PE20010540 A1 PE 20010540A1
Authority
PE
Peru
Prior art keywords
stylbene
composition
phytoalexins
influenza
prophylaxis
Prior art date
Application number
PE2000000750A
Other languages
Spanish (es)
Inventor
Seymour Gantenberg Nicholas
Ernest Singer Robert
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20010540A1 publication Critical patent/PE20010540A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: a)DE 0,01% A 99,99% DE FITOALEXINAS ESTILBENICAS DE FORMULA I, DONDE: R1, R2, R3, R4, R5 Y R6 SON H, OH, TAL COMO TRIHIDROXIESTILBENO, TETRAHIDROXIESTILBENO, 3,4`,5-TRIHIDROXIESTILBENO RESVERATROL; PRODUCTOS, EXTRACTOS, POLVOS DE FUENTES NATURALES DE FITOALEXINA ESTILBENICA; UN AGENTE MEJORADOR TAL COMO FENOLES, POLIFENOLES, ANTOCIAMINAS, ANTOCIANOSIDAS, CAROTENOIDES, BIOFLAVONOIDES, VITAMINAS, SALES MINERALES, ENTRE OTROS; b)AGENTES FARMACEUTICOS COMO ANTIHISTAMINICOS, ANTITUSIVO, ANTIINFLAMATORIO, ANALGESICO, ANTAGONISTA DE LEUCOTRIENO, METILXANTINA, ANTIOXIDANTE, ESTEROIDE, BRONCODILATADOR, ANTIVIRAL. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE SINTOMAS ASOCIADOS CON EL RESFRIADO Y ENFERMEDADES SIMILARES A INFLUENZAIT REFERS TO A COMPOSITION THAT INCLUDES: a) FROM 0.01% TO 99.99% OF STYLBENE PHYTOALEXINS OF FORMULA I, WHERE: R1, R2, R3, R4, R5 AND R6 ARE H, OH, SUCH AS TRIHYDROXYSTYLBENE, TETRAHYDROXYSTYLBENE , 3,4`, 5-TRIHYDROXYSTYLBENE RESVERATROL; PRODUCTS, EXTRACTS, POWDERS FROM NATURAL SOURCES OF PHYTOALEXIN STYLBENE; AN ENHANCING AGENT SUCH AS PHENOLS, POLYPHENOLS, ANTOCIAMINES, ANTOCIANOSIDES, CAROTENOIDS, BIOFLAVONOIDS, VITAMINS, MINERAL SALTS, AMONG OTHERS; b) PHARMACEUTICAL AGENTS SUCH AS ANTIHISTAMINES, ANTITUSSIVE, ANTI-INFLAMMATORY, ANALGESIC, LEUCOTRIENE ANTAGONIST, METHYLXANTHINE, ANTIOXIDANT, STEROID, BRONCHODILATOR, ANTIVIRAL. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT AND PROPHYLAXIS OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES

PE2000000750A 1999-07-30 2000-07-26 COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES PE20010540A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36494499A 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
PE20010540A1 true PE20010540A1 (en) 2001-05-15

Family

ID=23436803

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000750A PE20010540A1 (en) 1999-07-30 2000-07-26 COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES

Country Status (10)

Country Link
EP (1) EP1221949A2 (en)
JP (1) JP2003505500A (en)
CN (1) CN1377262A (en)
AU (1) AU6240200A (en)
CA (1) CA2379703A1 (en)
CO (1) CO5200850A1 (en)
HK (1) HK1049104A1 (en)
PE (1) PE20010540A1 (en)
TR (1) TR200200246T2 (en)
WO (1) WO2001008671A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ITRM20020562A1 (en) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti USE OF THE RESVERATROL FOR THE PREPARATION OF A USEFUL DRUG FOR THE TREATMENT OF INFLUENCE VIRUS INFECTIONS.
PL1845957T3 (en) 2005-02-04 2011-07-29 Peter Heger Method for producing a drug extract that contains hydroxystilbenes
ES2344920T3 (en) * 2006-03-28 2010-09-09 Epitech Group S.R.L. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY THE GENERAL RESPONSE OF THE IMMUTARY SYSTEM.
CN100453071C (en) * 2006-11-03 2009-01-21 李万忠 Oral resveratrol multi-phase liposome and preparation method thereof
WO2008136173A1 (en) * 2007-04-20 2008-11-13 Ochanomizu University Adipocyte differentiation inhibitor containing stilbene derivative as active ingredient
EP2231847B1 (en) 2008-01-08 2018-10-31 David Rubin Method and compositions for preserving wine
FR2933871B1 (en) * 2008-07-18 2012-12-14 Yvery FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE
PT2544705T (en) * 2010-03-12 2016-09-21 Synairgen Res Ltd Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
JP5848042B2 (en) 2011-06-29 2016-01-27 株式会社ロッテ Eye fatigue inhibiting composition and food and drink containing the same
AU2012325668A1 (en) * 2011-10-19 2014-05-08 Nad Life Pty Ltd Pharmaceutical compositions of resveratrol
CN106581028A (en) * 2016-11-30 2017-04-26 南宁市浩特竹鼠养殖场 Western medicine for curing cold of bamboo rat and preparation method of western medicine
US20230145555A1 (en) * 2020-04-10 2023-05-11 Galenus G.H. Ag Composition comprising resveratrol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753359A (en) * 1993-06-11 1995-02-28 Kao Corp Lipoxygenase inhibitor
FR2778337B1 (en) * 1998-05-05 2001-08-31 Inst Nat Sante Rech Med ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
CA2339049C (en) * 1998-09-08 2010-02-23 Cornell Research Foundation, Inc. Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
WO2001008671A2 (en) 2001-02-08
EP1221949A2 (en) 2002-07-17
WO2001008671A3 (en) 2002-05-02
JP2003505500A (en) 2003-02-12
CN1377262A (en) 2002-10-30
CO5200850A1 (en) 2002-09-27
CA2379703A1 (en) 2001-02-08
HK1049104A1 (en) 2003-05-02
AU6240200A (en) 2001-02-19
TR200200246T2 (en) 2002-09-23

Similar Documents

Publication Publication Date Title
PE20010540A1 (en) COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES
CO5190672A1 (en) COMPOSITION FOR ORAL DOSAGE, INSTANT DISSOLUTION
PE20001032A1 (en) COMPOSITIONS AND METHODS TO TREAT PULMONARY DISEASES
AR018143A1 (en) FORMULATION TO PREPARE A FAST DISINTEGRATION TABLET, FAST DISINTEGRATION TABLETS, ESPECIALLY COMPRESSED FAST DISINTEGRATION IN THE MOUTH
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
DE50211204D1 (en) CANNABIS EXTRACTS PHARMACEUTICAL COMPOSITION
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
PA8479201A1 (en) DERIVATIVES OF HYDROXY ACID-HYDROXAMIC PIPECOLATE
AR023129A1 (en) COMPOSITIONS TO IMPROVE FERTILITY
PT1239849E (en) Pharmaceutical formulations that comprise Resveratrol and its use
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
IL154888A (en) Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis
UY30761A1 (en) DERIVATIVES OF 2.3-DIHYDROIMIDAZO (1,2-C) SUBSTITUTED KINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS
AR023876A1 (en) COMPOSITIONS FOR THE TREATMENT OF ESOFAGIC AFFECTIONS.
BR0209283A (en) Method for the manufacture of a low dosage pharmaceutical composition having uniform drug distribution and potency
ES2188663T3 (en) USE OF PRODUCTS CONTAINING MAGNESIUM FOR THE TREATMENT OR PROFILAXIS OF NEOPLASICAL OR AUTOIMMUNE DISEASES.
AR049518A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A SILICONE AGENT AND TWO SOLUBILIZED ACTIVE PRINCIPLES
ECSP055820A (en) UNIT FOR DAILY DOSAGE OF MELATONIN
MY203497A (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
AR070593A1 (en) EFFECTIVE COMPOSITIONS
ES2124983T5 (en) USE OF AN SUBSTANCE ANTAGONIST P FOR THE TREATMENT OF RED CUTANEOUS STAINS OF NEUROGEN ORIGIN.
WO2002100404A3 (en) Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
PA8549401A1 (en) COMPLEX THAT INCLUDES INHIBITING FACTOR OF OSTEOCLASTOGENESIS AND POLISACARIDO
AR019327A1 (en) COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION
CO2022011987A2 (en) Uses and compositions based on polyphenols to improve the oral bioavailability of hydroxytyrol

Legal Events

Date Code Title Description
FC Refusal